# KYTX (Kyverna Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Kyverna Therapeutics, Inc. reported $189.4M in total assets and a net loss of $157.8M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/KYTX
- Markdown: https://convexityos.com/fundamentals/KYTX.md
- SEC CIK: 0001994702
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:40 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001994702&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$163.1M | Operating profit |
| Net Income | FY 2025 | -$157.8M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$2.55 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$153.7M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $170.6M | Total debt: $32.45M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $133.7M | $112.5M | $49.92M |
| Total Operating Expenses | $169.8M | $142.6M | $62.41M |
| **Operating Income** | -$169.8M | -$142.6M | -$62.41M |
| **EBITDA** | -$168.0M | -$140.5M | -$60.70M |
| Interest Income | $9.09M | $15.36M | $2.28M |
| Interest Expense | $489K | $142K | $187K |
| Income Tax Expense | $0 | $0 | $0 |
| **Net Income** | -$161.3M | -$127.5M | -$60.37M |
| Basic EPS | -$3.64 | -$3.33 | -$89.61 |
| **Diluted EPS** | -$3.64 | -$3.33 | -$89.61 |
| Basic Shares Outstanding | 44.3M | 38.3M | 673.6K |
| Diluted Shares Outstanding | 44.3M | 38.3M | 673.6K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $27.02M | $24.79M | $30.07M | $30.01M | $30.46M | $35.82M | $37.43M | $33.48M |
| Total Operating Expenses | $42.90M | $39.56M | $41.37M | $39.28M | $38.73M | $44.41M | $47.41M | $41.04M |
| **Operating Income** | -$42.90M | -$39.56M | -$41.37M | -$39.28M | -$38.73M | -$44.41M | -$47.41M | -$41.04M |
| **EBITDA** | -$42.62M | -$39.12M | -$41.02M | -$38.91M | -$38.31M | -$43.90M | -$46.91M | -$40.48M |
| Interest Income | $1.68M | $1.93M | $2.33M | $1.91M | $2.00M | $2.36M | $2.83M | $3.58M |
| Interest Expense | $728K | $674K | $667K | $444K | $7.0K | $14K | $25K | $27K |
| **Net Income** | -$41.94M | -$38.32M | -$39.73M | -$37.80M | -$36.79M | -$42.08M | -$44.63M | -$37.49M |
| Basic EPS | -$0.68 | -$0.63 | -$0.66 | -- | -$0.85 | -$0.97 | -$1.03 | -- |
| **Diluted EPS** | -$0.68 | -$0.63 | -$0.66 | -- | -$0.85 | -$0.97 | -$1.03 | -- |
| Basic Shares Outstanding | 62.0M | 60.9M | 60.4M | -- | 43.4M | 43.2M | 43.2M | -- |
| Diluted Shares Outstanding | 62.0M | 60.9M | 60.4M | -- | 43.4M | 43.2M | 43.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $124.1M | $96.62M | $34.65M |
| Short-Term Investments | $155.2M | $189.4M | $22.90M |
| **Cash & Short-Term Investments** | $279.3M | $286.0M | $57.54M |
| **Total Current Assets** | $283.0M | $290.6M | $60.66M |
| Property, Plant & Equipment, Net | $1.55M | $3.35M | $2.33M |
| Other Non-Current Assets | $4.90M | $2.84M | $3.36M |
| **Total Non-Current Assets** | $10.87M | $14.04M | $14.53M |
| **Total Assets** | $293.8M | $304.6M | $75.19M |
| Accounts Payable | $5.31M | $4.62M | $4.36M |
| **Total Current Liabilities** | $36.49M | $33.76M | $19.86M |
| Long-Term Debt | $24.74M | -- | -- |
| **Total Non-Current Liabilities** | $25.06M | $4.30M | $6.16M |
| **Total Liabilities** | $61.55M | $38.06M | $26.02M |
| **Total Debt (incl. Leases)** | $29.03M | $8.24M | $9.08M |
| Common Stock | $1.0K | $0 | -- |
| Retained Earnings | -$424.8M | -$263.5M | -$136.0M |
| Accumulated Other Comp. Income | $97K | $105K | $4.0K |
| **Total Stockholders' Equity** | $232.3M | $266.6M | -$13.14M |
| Total Equity | $232.3M | $266.6M | -$13.14M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $31.82M | $31.81M | $32.19M | $124.1M | $34.16M | $53.44M | $56.87M | $96.62M |
| Short-Term Investments | $138.8M | $167.6M | $204.3M | $155.2M | $137.0M | $158.2M | $185.8M | $189.4M |
| **Cash & Short-Term Investments** | $170.6M | $199.4M | $236.4M | $279.3M | $171.1M | $211.7M | $242.6M | $286.0M |
| **Total Current Assets** | $176.3M | $206.5M | $241.7M | $283.0M | $174.9M | $214.3M | $247.7M | $290.6M |
| Property, Plant & Equipment, Net | $1.36M | $1.33M | $1.34M | $1.55M | $1.79M | $2.16M | $2.44M | $3.35M |
| Other Non-Current Assets | $3.73M | $3.44M | $5.01M | $4.90M | $5.36M | $4.05M | $3.64M | $2.84M |
| **Total Non-Current Assets** | $13.18M | $13.28M | $15.30M | $10.87M | $12.23M | $12.18M | $13.00M | $14.04M |
| **Total Assets** | $189.4M | $219.8M | $257.0M | $293.8M | $187.2M | $226.5M | $260.7M | $304.6M |
| Accounts Payable | $3.40M | $2.93M | $11.60M | $5.31M | $3.02M | $9.92M | $8.47M | $4.62M |
| **Total Current Liabilities** | $25.14M | $22.80M | $29.67M | $36.49M | $33.87M | $39.79M | $33.29M | $33.76M |
| Long-Term Debt | $24.96M | $24.88M | -- | $24.74M | -- | -- | -- | -- |
| **Total Non-Current Liabilities** | $31.15M | $31.47M | $31.77M | $25.06M | $1.34M | $2.34M | $3.35M | $4.30M |
| **Total Liabilities** | $56.28M | $54.27M | $61.44M | $61.55M | $35.21M | $42.13M | $36.65M | $38.06M |
| **Total Debt (incl. Leases)** | $32.45M | $33.00M | $8.94M | $29.03M | $5.02M | $5.92M | $6.94M | $8.24M |
| Common Stock | $1.0K | $1.0K | $1.0K | $1.0K | -- | -- | -- | $0 |
| Retained Earnings | -$544.8M | -$502.9M | -$464.6M | -$424.8M | -$387.0M | -$350.2M | -$308.2M | -$263.5M |
| Accumulated Other Comp. Income | -$151K | -$142K | -$96K | $97K | $29K | -$20K | -$1.0K | $105K |
| **Total Stockholders' Equity** | $133.2M | $165.5M | $195.6M | $232.3M | $151.9M | $184.4M | $224.0M | $266.6M |
| Total Equity | $133.2M | $165.5M | $195.6M | $232.3M | $151.9M | $184.4M | $224.0M | $266.6M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$161.3M | -$127.5M | -$60.37M |
| Depreciation & Amortization | $1.80M | $2.13M | $1.71M |
| Stock-Based Compensation | $10.08M | $8.36M | $2.22M |
| Change in Payables | $543K | $736K | $4.08M |
| **Operating Cash Flow** | -$153.7M | -$114.2M | -$52.41M |
| Capital Expenditure | -$5.0K | -$2.21M | -$621K |
| **Free Cash Flow** | -$153.7M | -$116.5M | -$53.03M |
| Purchases of Investments | -$364.6M | -$490.0M | -$54.85M |
| **Investing Cash Flow** | $40.02M | -$160.9M | -$8.79M |
| Common Stock Issued | $16.94M | $0 | -- |
| **Financing Cash Flow** | $141.2M | $337.1M | $58.12M |
| **Net Change in Cash** | $27.47M | $61.96M | -$3.08M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$41.94M | -$38.32M | -$39.73M | -$37.80M | -$36.79M | -$42.08M | -$44.63M | -$37.49M |
| Depreciation & Amortization | $274K | $434K | $351K | $368K | $415K | $515K | $501K | $563K |
| Stock-Based Compensation | $3.62M | $3.51M | $3.17M | $2.70M | $2.70M | $2.52M | $2.16M | $1.38M |
| Change in Payables | $469K | -$8.65M | $6.28M | $2.15M | -$6.80M | $1.41M | $3.78M | -$5.30M |
| **Operating Cash Flow** | -$35.37M | -$40.31M | -$41.60M | -$33.53M | -$43.32M | -$31.95M | -$44.91M | -$37.06M |
| Capital Expenditure | -- | -- | -- | $1.0K | -$2.0K | -$4.0K | $0 | -$532K |
| **Free Cash Flow** | -- | -- | -- | -$33.53M | -$43.32M | -$31.95M | -$44.91M | -$37.59M |
| Purchases of Investments | -$46.15M | -$31.92M | -$115.9M | -$116.0M | -$72.82M | -$94.73M | -$81.12M | -$127.2M |
| **Investing Cash Flow** | $28.52M | $36.13M | -$50.20M | -$17.29M | $22.56M | $29.17M | $5.58M | $29.22M |
| **Financing Cash Flow** | $6.86M | $3.79M | -$101K | $140.7M | $1.49M | -$649K | -$414K | -$215K |
| **Net Change in Cash** | $12K | -$388K | -$91.90M | $89.93M | -$19.28M | -$3.43M | -$39.75M | -$8.05M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Equity (ROE) | -69.4% | -47.8% | -- |
| Return on Assets (ROA) | -54.9% | -41.8% | -80.3% |
| Current Ratio | 7.75x | 8.61x | 3.05x |
| Quick Ratio | 7.65x | 8.47x | 2.90x |
| Debt to Equity | 0.12x | 0.03x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -118.5% | -92.2% | -80.0% | -69.4% | -106.0% | -86.1% | -64.9% | -47.8% |
| Return on Assets (ROA) | -83.3% | -69.4% | -60.9% | -54.9% | -86.0% | -70.1% | -55.8% | -41.8% |
| Current Ratio | 7.01x | 9.06x | 8.15x | 7.75x | 5.16x | 5.39x | 7.44x | 8.61x |
| Quick Ratio | 6.79x | 8.74x | 7.97x | 7.65x | 5.05x | 5.32x | 7.29x | 8.47x |
| Debt to Equity | 0.24x | 0.20x | 0.05x | 0.12x | 0.03x | 0.03x | 0.03x | 0.03x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
